Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
/in Glioblastoma, International Publications, IOZK VeröffentlichungenTherapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsActive immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International PublicationsRole of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL.
/in Glioblastoma, International Publications, Newcastle Disease VirusOutcome of an advanced anaplastic astrocytoma patient treated with Newcastle disease viral (NDV) oncolytic therapy.
/in Glioblastoma, International Publications, Newcastle Disease VirusThe natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
/in Dendritic Cells, Glioblastoma, International PublicationsVaccine strategies for glioblastoma: progress and future directions
/in Dendritic Cells, Glioblastoma, International PublicationsComparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
/in Dendritic Cells, Glioblastoma, International Publicationsα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer